HSCS
HeartSciences Inc.
$1.80
-4.26%
$5.7M
No data for this timeframe.
Vol
Market Cap$5.7M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders3 funds
Inst. Value$86.7K
Inst. Activity1 buys / 0 sells
Press Releases1
Exchange Nasdaq·Sector Orthopedic, Prosthetic & Surgical Appliances & Supplies·Inc. TX·CIK 0001468492·Prev Close $1.88
Recent Activity
Inst.
BANK OF AMERICA CORP — ADD
26 shares ($80.00)
Inst.
BANK OF AMERICA CORP — ADD
19 shares ($66.00)
Jun 2, 2026
other
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Bunkerhill Health’s FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction beco
Mar 16, 2026
Press
HeartSciences Inc. reported financial results for its fiscal third quarter ended January 31, 2026, along with a business
Impact 3/10
Price Targets
$10.00
+455.6% upside
Strong Buy
Current $1.80
Low $8.00
Median $10.00
High $12.00
2 analysts
$8.00
$12.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 24, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Dec 22, 2025 | Ascendiant Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.67 ▲ +20.7% | $-0.68 — $-0.66 | 64% YoY | 2 |
| Next Q | $-0.71 ▲ +12.8% | $-0.73 — $-0.70 | 55% YoY | 2 |
| Current FY | $-3.38 ▲ +11.6% | $-3.47 — $-3.28 | 64% YoY | 2 |
| Next FY | $-2.83 ▲ +11.4% | $-3.10 — $-2.55 | 16% YoY | 2 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $44.2K | — |
| VANGUARD FIDUCIARY TRUST CO | $42.4K | — |
| WELLS FARGO & COMPANY/MN | $63.00 | — |
3 institutional holders with $86.7K total value (35,232 shares) as of 2026-Q1. Top holders: VANGUARD, VANGUARD, WELLS.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 17,968 | $44.2K | 51.0% | — |
| 2 | VANGUARD FIDUCIARY TRUST CO | 17,239 | $42.4K | 48.9% | — |
| 3 | WELLS FARGO & COMPANY/MN | 25 | $63.00 | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 19 | 26 | +36.8% | $80.00 | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 10 | 19 | +90.0% | $66.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 1,305 | 2,625 | +101.1% | $7.4K | 2025-Q1 |
| UBS Group AG | ADD | 681 | 1,305 | +91.6% | $5.0K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 4 | 7 | +75.0% | $34.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$10.00 mean target
+455.6% upside
Strong Buy (3.00)
$8.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $1.80 |
| Target Low | $8.00 |
| Target Mean | $10.00 |
| Target Median | $10.00 |
| Target High | $12.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-04-30 |
$-0.67 | $-0.68 | $-0.66 | 64.4% | +20.7% | 2↑ 0↓ | $0.0B | -100.0% | 2 |
| Next Q 2026-07-31 |
$-0.71 | $-0.73 | $-0.70 | 54.8% | +12.8% | 2↑ 0↓ | $0.0B | 2531.6% | 2 |
| Current FY 2026-04-30 |
$-3.38 | $-3.47 | $-3.28 | 63.9% | +11.6% | 2↑ 0↓ | $0.0B | -1.1% | 2 |
| Next FY 2027-04-30 |
$-2.83 | $-3.10 | $-2.55 | 16.3% | +11.4% | 2↑ 0↓ | $0.0B | 8214.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.670 | |
| 7d ago | $-0.845 | +0.175 |
| 30d ago | $-0.845 | +0.175 |
| 60d ago | $-0.845 | +0.175 |
| 90d ago | $-0.845 | +0.175 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 24, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | Ascendiant Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Bunkerhill Health’s FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available t
May 19, 2026
other
HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
Agreement follows Cibolo Health’s endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial mome
May 5, 2026
other
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
Agreement with St. Vincent Health marks HeartSciences’ transition from early adopter installations to commercial SaaS deployments following the full l
Apr 14, 2026
routine
HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
<p>Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=-Nc-CjK2P6t5UMQRc6uNCkA40kEaojA9v_RtCTDCXed
Mar 25, 2026
other
HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
<p>Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=FaDY39T04J6cEDeGkaDnbrl21-sfvfhFMCcVNEfDzK
Mar 24, 2026
other
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
<p>Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=zU7RPsynk5vnuBIAGkjeVqWoHCZWKPXJlNwdNY1Yk9p
Mar 16, 2026
earnings
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
<p>Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=wZMaFePypMnXXXa9tOdfZJYTBZOxdaFUdND8FrEm
Mar 12, 2026
earnings_calendar
HSCS Q3 2026 Earnings Scheduled — 2026-03-12